Richard N. Fedorak

37.9k total citations · 13 hit papers
393 papers, 27.2k citations indexed

About

Richard N. Fedorak is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Richard N. Fedorak has authored 393 papers receiving a total of 27.2k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Genetics, 152 papers in Epidemiology and 118 papers in Surgery. Recurrent topics in Richard N. Fedorak's work include Inflammatory Bowel Disease (190 papers), Microscopic Colitis (134 papers) and Helicobacter pylori-related gastroenterology studies (59 papers). Richard N. Fedorak is often cited by papers focused on Inflammatory Bowel Disease (190 papers), Microscopic Colitis (134 papers) and Helicobacter pylori-related gastroenterology studies (59 papers). Richard N. Fedorak collaborates with scholars based in Canada, United States and Belgium. Richard N. Fedorak's co-authors include Brian G. Feagan, Paul Rutgeerts, Karen Madsen, William J. Sandborn, Remo Panaccione, Karen I. Kroeker, Douglas C. Wolf, Gary Wild, Stephen B. Hanauer and Daniel Sadowski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Richard N. Fedorak

385 papers receiving 26.3k citations

Hit Papers

Vedolizumab as Induction and Maint... 1994 2026 2004 2015 2013 2004 2020 2006 2007 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
    2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
  2. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
    2004 1.6k citations Bruce E. Sands, Brian G. Feagan et al. New England Journal of Medicine profile →
  3. An overview of clinical decision support systems: benefits, risks, and strategies for success
    2020 1.4k citations Richard N. Fedorak, Karen I. Kroeker et al. profile →
  4. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
    2006 1.3k citations William J. Sandborn, Paul Rutgeerts et al. Gastroenterology profile →
  5. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
    2007 798 citations William J. Sandborn, S. B. Hanauer et al. profile →
  6. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
    2011 683 citations William J. Sandborn, Remo Panaccione et al. profile →
  7. Methotrexate for the Treatment of Crohn's Disease
    1995 651 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →
  8. A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
    2008 592 citations William J. Sandborn, Brian G. Feagan et al. Gastroenterology profile →
  9. Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice
    1999 588 citations Karen Madsen, Richard N. Fedorak et al. Gastroenterology profile →
  10. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
    1994 581 citations Brian G. Feagan, Richard N. Fedorak et al. Gastroenterology profile →
  11. VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis
    2005 552 citations Richard N. Fedorak, Karen Madsen et al. The American Journal of Gastroenterology profile →
  12. Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
    2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →
  13. A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
    2000 530 citations Brian G. Feagan, Richard N. Fedorak et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard N. Fedorak Canada 71 15.4k 11.8k 6.7k 5.4k 4.3k 393 27.2k
Subrata Ghosh United Kingdom 81 17.1k 1.1× 12.2k 1.0× 8.5k 1.3× 5.9k 1.1× 5.1k 1.2× 590 31.0k
Toshifumi Hibi∥ Japan 81 9.9k 0.6× 8.3k 0.7× 7.6k 1.1× 7.1k 1.3× 5.3k 1.2× 788 26.6k
Gilaad G. Kaplan Canada 76 15.7k 1.0× 13.3k 1.1× 11.2k 1.7× 4.5k 0.8× 6.2k 1.4× 486 34.2k
Remo Panaccione Canada 81 26.4k 1.7× 19.4k 1.6× 10.1k 1.5× 8.2k 1.5× 4.4k 1.0× 704 36.7k
Marc Ferrante Belgium 64 12.4k 0.8× 8.9k 0.8× 5.3k 0.8× 4.7k 0.9× 4.6k 1.1× 543 21.4k
Anne M. Griffiths Canada 77 16.1k 1.0× 11.3k 1.0× 7.3k 1.1× 3.6k 0.7× 2.6k 0.6× 363 23.0k
Julián Panés Spain 84 14.2k 0.9× 11.2k 0.9× 8.5k 1.3× 4.8k 0.9× 2.8k 0.6× 590 26.0k
Bruce E. Sands United States 82 28.6k 1.9× 20.9k 1.8× 10.8k 1.6× 9.9k 1.9× 4.5k 1.0× 596 39.6k
Gert Van Assche Belgium 92 26.9k 1.8× 20.6k 1.7× 10.7k 1.6× 8.9k 1.7× 3.2k 0.7× 476 36.8k
Ashwin N. Ananthakrishnan United States 76 11.6k 0.8× 10.6k 0.9× 5.8k 0.9× 2.4k 0.5× 4.4k 1.0× 498 22.5k

Countries citing papers authored by Richard N. Fedorak

Since Specialization
Citations

This map shows the geographic impact of Richard N. Fedorak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard N. Fedorak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard N. Fedorak more than expected).

Fields of papers citing papers by Richard N. Fedorak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard N. Fedorak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard N. Fedorak. The network helps show where Richard N. Fedorak may publish in the future.

Co-authorship network of co-authors of Richard N. Fedorak

This figure shows the co-authorship network connecting the top 25 collaborators of Richard N. Fedorak. A scholar is included among the top collaborators of Richard N. Fedorak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard N. Fedorak. Richard N. Fedorak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Christopher, Leonardo Guizzetti, Remo Panaccione, et al.. (2018). Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Alimentary Pharmacology & Therapeutics. 47(12). 1578–1596. 24 indexed citations
2.
3.
Ma, Christopher, Richard N. Fedorak, Gilaad G. Kaplan, et al.. (2017). Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology & Therapeutics. 45(9). 1232–1243. 123 indexed citations
4.
Ma, Christopher, Remo Panaccione, Richard N. Fedorak, et al.. (2017). Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology. 16(5). 637–647.e13. 45 indexed citations
5.
Kokai‐Kun, John F., Tracey Roberts, Éric Sicard, et al.. (2017). The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies. Antimicrobial Agents and Chemotherapy. 61(3). 57 indexed citations
6.
Deng, Lu, Hong Fang, Yuanyuan Sun, et al.. (2016). Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. International Journal of Colorectal Disease. 32(5). 741–743. 22 indexed citations
7.
Cheung, Justin, Karen J. Goodman, Safwat Girgis, et al.. (2014). Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns. BMJ Open. 4(1). e003689–e003689. 26 indexed citations
8.
Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 369(8). 711–721. 2011 indexed citations breakdown →
9.
Kelly, Ciarán P., P. H. R. Green, Joseph A. Murray, et al.. (2012). Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study. Alimentary Pharmacology & Therapeutics. 37(2). 252–262. 155 indexed citations
10.
Hotte, Naomi, Saad Y. Salim, Eric J. Albert, et al.. (2012). Patients with Inflammatory Bowel Disease Exhibit Dysregulated Responses to Microbial DNA. PLoS ONE. 7(5). e37932–e37932. 30 indexed citations
11.
Goodman, Karen J., et al.. (2011). Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflammatory Bowel Diseases. 18(1). 34–40. 75 indexed citations
12.
Cheung, Justin, Robert J. Bailey, Sander Veldhuyzen van Zanten, et al.. (2008). Early Experience with Unsedated Ultrathin 4.9 mm Transnasal Gastroscopy: A Pilot Study. SHILAP Revista de lepidopterología. 22(11). 917–922. 10 indexed citations
13.
Fedorak, Richard N. & Levinus A. Dieleman. (2008). Probiotics in the Treatment of Human Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology. 42(Supplement 2). S97–S103. 23 indexed citations
14.
Guarner, Francisco, James Garisch, Alfred Gangl, et al.. (2008). World Gastroenterology Organisation Practice Guideline : Probiotics and Prebiotics - May 2008 : guideline. 6(2). 14–25. 10 indexed citations
15.
Hanauer, S. B., William J. Sandborn, P. Rutgeerts, et al.. (2005). Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study. The American Journal of Gastroenterology. 100. S313–S314.
16.
Barkun, Alan, Robert Enns, David Armstrong, et al.. (2004). The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic Hemostasis and Proton Pump Inhibition are Associated with Improved Outcomes in a Real-Life Setting. The American Journal of Gastroenterology. 99(7). 1238–1246. 270 indexed citations
17.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2003). A RANDOMIZED CONTROLLED TRIAL OF A HUMANIZED ALPHA4BETA7 ANTIBODY IN ULCERATIVE COLITIS (UC). The American Journal of Gastroenterology. 98. S248–S249. 4 indexed citations
18.
Fedorak, Richard N., Alfred Gangl, Charles O. Elson, et al.. (2000). Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology. 119(6). 1473–1482. 386 indexed citations
19.
Fedorak, Richard N., et al.. (1999). Trace Element Contamination of Total Parenteral Nutrition. 1. Contribution of Component Solutions. Journal of Parenteral and Enteral Nutrition. 23(4). 222–227. 83 indexed citations
20.
Fedorak, Richard N., Eugene B. Chang, James Madara, & Michael Field. (1987). Intestinal adaptation to diabetes. Altered Na-dependent nutrient absorption in streptozocin-treated chronically diabetic rats.. Journal of Clinical Investigation. 79(6). 1571–1578. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Subrata Ghosh Breakdown of academic impact, for papers by Toshifumi Hibi∥ Breakdown of academic impact, for papers by Gilaad G. Kaplan Breakdown of academic impact, for papers by Remo Panaccione Breakdown of academic impact, for papers by Marc Ferrante Breakdown of academic impact, for papers by Anne M. Griffiths Breakdown of academic impact, for papers by Julián Panés Breakdown of academic impact, for papers by Bruce E. Sands Breakdown of academic impact, for papers by Gert Van Assche Breakdown of academic impact, for papers by Ashwin N. Ananthakrishnan
Rankless by CCL
2026